Author

Q. J. Khan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Assay:scRNA-seq· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

F. R. Adler· 2 shared J. Chen· 2 shared J. I. Griffiths· 2 shared J. T. Chang· 2 shared P. A. Cosgrove· 2 shared , I. Makhoul· 1 shared A. Bardia· 1 shared A. Bild· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. R. Adler

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion

R. Kudo, A. Safonov, E. M. da Silva, Q. Li, H. Shao, M. Will, A. Fushimi, H. Nakshatri, J. S. Reis-Filho, S. Goel, A. Koff, B. Weigelt, Q. J. Khan, P. Razavi, S. Chandarlapaty

The paper identifies TP53 loss and MDM2 amplification as factors associated with poor long-term response to CDK4/6 inhibition in breast cancer and shows that CDK2 inhibition can overcome this resistance.

bioRxiv · Aug 25, 2023Cancer Biology

Cancer cells communicate with macrophages to prevent T cell activation during development of cell cycle therapy resistance

J. I. Griffiths, P. A. Cosgrove, E. Medina Castaneda, A. Nath, J. Chen, F. R. Adler, J. T. Chang, Q. J. Khan, A. H. Bild

The paper shows cancer cells in resistant tumors promote immune-suppressive macrophages, reducing T-cell activation, and suggests balancing cell cycle inhibition with immune activation for better therapy.

bioRxiv · Sep 14, 2022 · PreprintCancer Biology

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitors

J. I. Griffiths, J. Chen, P. A. Cosgrove, A. O'Dea, P. Sharma, C. Ma, M. Trivedi, K. Kalinsky, K. B. Wisinski, R. O'Regan, , I. Makhoul, L. M. Spring, A. Bardia, F. R. Adler, A. L. Cohen, , A. Bild

This study examines how breast cancer tumors evolve during early stage treatment with combination CDK and endocrine inhibitors, finding convergent resistance pathways and increased subclonal diversity with combination therapy.

bioRxiv · Jan 19, 2021 · PreprintCancer Biology